Drug delivery device

Abstract

To provide drug delivery devices and related arrangements.SOLUTION: A drug delivery device 10 may include a housing 12 having an opening 14, a drug storage container 20 including a delivery member 16 with an insertion end 28 configured to extend at least partially through the opening 14, and a plunger 26. A drive mechanism 30 may be included for driving the plunger 26 in a distal direction to expel a drug from the drug storage container 20 through the delivery member 16 upon activation. The drug delivery device 10 may additionally include a guard 32 movably disposed adjacent to the opening 14 and operably coupled to the drive mechanism 30 for activation of the drive mechanism 30. A lock 40 may be selectively engageable with the guard 32 to limit movement of the guard 32 in the proximal direction. An indicator 70 may be coupled to the drive mechanism 30 to generate an audible signal during drug delivery, and to cease generating the audible signal when drug delivery is complete.SELECTED DRAWING: Figure 5

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 908,472, entitled "Drug Delivery Device," filed September 30, 2019, and U.S. Provisional Patent Application No. 62 / 975,557, entitled "Drug Delivery Device," filed February 12, 2020, each of which is incorporated herein by reference.

[0002] The present disclosure relates to drug delivery devices and, more particularly, to the safe and proper handling of such devices before, during, and after injection. [Background technology]

[0003] Universal aversion to exposed needles, as well as health and safety concerns, have led to the development of drug delivery devices that conceal the needle or other insertion member prior to use and automate various aspects of the injection process. Such devices offer various advantages over traditional methods of drug delivery, including, for example, delivery via a conventional syringe.

[0004] Many drug delivery devices have limited visual access to the internal structure of the device to mitigate device complexity and user concerns. As a result, users may not accurately determine the amount of drug remaining in the device and may therefore prematurely remove the device from the injection site before the full dose has been administered. Conversely, users may take the opposite approach and hold the device against the injection site for an excessively long time to ensure that the full dose has been administered. Doing so may cause discomfort, doubt, and / or anxiety to the user.

[0005] To reduce complexity, some drug delivery devices do not incorporate a mechanism for retracting the needle within the housing after administration is complete. Therefore, when the device is removed from the injection site, the needle may protrude outside the housing. To cover the exposed needle in the post-delivery state, certain devices deploy a spring-loaded guard from within the device. However, if an external force greater than the spring's biasing force is applied to the guard, the needle may be exposed again. Therefore, ensuring that the guard hides the needle in the post-delivery state is a consideration. Summary of the Invention [Means for solving the problem]

[0006] The present disclosure describes a drug delivery device that embodies an advantageous alternative to existing drug delivery devices and that may address one or more of the problems or needs mentioned herein.

[0007] One aspect of the present disclosure provides a drug delivery device including a housing having an opening, a drug reservoir, a plunger, a drive mechanism, a guard, a lock, and an indicator. The drug reservoir may include a delivery member having an insertion end configured to extend at least partially through the opening in the housing. The drive mechanism may be operable to drive the plunger in a distal direction to expel the drug from the drug reservoir through the delivery member. The guard may be movably disposed adjacent the opening and operably coupled to the drive mechanism. The lock may be selectively engageable with the guard to limit movement of the guard in a proximal direction. The indicator may be coupled to the drive mechanism to generate an audible signal during drug delivery.

[0008] Another aspect of the present disclosure provides a drug delivery device including a housing having an opening, a drug storage container, a plunger, a drive mechanism, a guard, and a lock. The drug storage container may include a delivery member having an insertion end configured to extend at least partially through the opening in the housing. The drive mechanism may be operable to drive the plunger distally to expel the drug from the drug storage container through the delivery member. The guard may be movably disposed adjacent to the opening and operably coupled to the drive mechanism. Proximal movement of the guard relative to the housing may cause the guard to directly or indirectly actuate the drive mechanism. The lock may be at least partially disposed within the guard and rotatable between a first rotational position in which the lock allows proximal movement of the guard and a second rotational position in which the lock restricts proximal movement of the guard.

[0009] A further aspect of the present disclosure provides an arrangement for a drug delivery device. The arrangement may include a guard and a lock. The guard may be configured to selectively cover an insertion end of a delivery member of the drug delivery device. Furthermore, the guard may have an extended position in which the guard at least partially extends through an opening in a housing of the drug delivery device and a retracted position in which the guard is positioned away from the extended position. The lock may be rotatable between a first rotational position in which the lock allows movement of the guard from the extended position to the retracted position and a second rotational position in which the lock restricts movement of the guard from the extended position to the retracted position.

[0010] An additional aspect of the present disclosure provides a drug delivery device including a housing having an opening, a drug reservoir, a plunger, a drive mechanism, and an indicator. The drug reservoir can include a delivery member having an insertion end configured to extend at least partially through the opening in the housing. The drive mechanism can be operable to drive the plunger distally to expel the drug from the drug reservoir through the delivery member.

[0011] Another aspect of the present disclosure provides a drug delivery device including a drug reservoir including a housing having an opening, a plunger, a drive mechanism, an end cap removably coupled to the housing adjacent the opening when in the storage position, and a delivery member having an insertion end configured to extend at least partially through the opening of the housing. The drive mechanism can be operable to drive the plunger to expel the drug from the drug reservoir through the delivery member. The housing can include a housing rotation inhibitor. The end cap can include an end cap rotation inhibitor that is adjacent to and substantially aligned with the housing rotation inhibitor when the end cap is in the storage position.

[0012] A further aspect of the present disclosure provides a method of assembling a drug delivery device, which may include (i) providing a guard configured to selectively cover an insertion end of a delivery member of the drug delivery device, (ii) disposing a lock at least partially within the guard, the lock being rotatable between a first rotational position where the lock allows movement of the guard relative to the delivery member and a second rotational position where the lock limits movement of the guard relative to the delivery member, and (iii) determining whether a first opening in the guard is rotationally aligned with a second opening in the lock.

[0013] A further aspect of the present disclosure provides a drug delivery device including a housing having an opening, a drug reservoir, a plunger, a rotary biasing member, and a mechanical linkage. The drug reservoir may include a delivery member having a housing portion defining a longitudinal axis and an insertion end configured to extend at least partially through the opening during a delivery state. The plunger may be distally movable to expel the drug from the drug reservoir through the delivery member. The rotary biasing member may be configured to be initially held in a biased state and to rotate about the longitudinal axis when released. The mechanical linkage may be operably coupled to the plunger and the rotary biasing member. Furthermore, the mechanical linkage may be configured to convert rotation resulting from release of the rotary biasing member into distal movement of the plunger.

[0014] It is believed that the present disclosure will be more fully understood when the following description is read in conjunction with the accompanying drawings. Some drawings may be simplified by selectively omitting elements to more clearly show other elements. The omission of such elements in some drawings does not necessarily indicate the presence or absence of the particular element in any of the illustrative embodiments, unless expressly described in the corresponding written specification. Additionally, none of the drawings are necessarily drawn to scale. [Brief explanation of the drawings]

[0015] [Figure 1A] FIG. 1 is a perspective view of a drug delivery device according to an embodiment of the present disclosure in a pre-delivery state. [Figure 1B] FIG. 1B is a cross-sectional view of the drug delivery device of FIG. 1A. [Figure 2A] FIG. 1B is a cross-sectional view of the rear subassembly of the drug delivery device of FIG. 1A. [Figure 2B] FIG. 1B is a perspective view of a drug reservoir of the drug delivery device of FIG. 1A. [Figure 2C] FIG. 1B is a cross-sectional view of a front subassembly of the drug delivery device of FIG. 1A. [Figure 3] FIG. 1B is an exploded view of the drug delivery device of FIG. 1A. [Figure 4] 1B is a cross-sectional view of the drug delivery device of FIG. 1A after removal of the removable cap by a user. [Figure 5] FIG. 1B is a cross-sectional view of the drug delivery device of FIG. 1A positioned at an injection site prior to activation. [Figure 6] 1B is a cross-sectional view of the drug delivery device of FIG. 1A after being actuated to initiate drug delivery. [Figure 7] Same view as Figure 6, but the latter at a moment during delivery. [Figure 8] FIG. 1B is a cross-sectional view of the drug delivery device of FIG. 1A, with the stopper positioned in the end-of-dosing position. [Figure 9]1B is a cross-sectional view of the drug delivery device of FIG. 1A after drug delivery is completed and the drug delivery device has been removed from the injection site. [Figure 10] FIG. 1 is an exploded view of an arrangement including a rear cover and a display according to an embodiment of the present disclosure. [Figure 11] FIG. 11 is a cross-sectional view of the arrangement of FIG. 10. [Figure 12] 12 is a cross-sectional view taken along line ZZ in FIG. 11. [Figure 13] FIG. 10 is a cross-sectional view of a display according to another embodiment of the present disclosure. [Figure 14] FIG. 10 is a cross-sectional view of a display according to another embodiment of the present disclosure. [Figure 15] FIG. 10 is a cross-sectional view of a display according to another embodiment of the present disclosure. [Figure 16] FIG. 10 is a cross-sectional view of a display according to another embodiment of the present disclosure. [Figure 17] FIG. 10 is a cross-sectional view of a display according to another embodiment of the present disclosure. [Figure 18] FIG. 10 is a cross-sectional view of a rear cover according to an embodiment of the present disclosure. [Figure 19] FIG. 19 is an enlarged view of a portion of FIG. 18. [Figure 20] FIG. 10 is a cross-sectional view of a rear cover according to another embodiment of the present disclosure. [Figure 21] FIG. 21 is an enlarged view of a portion of FIG. 20. [Figure 22] FIG. 1 is a perspective view of a locking arrangement according to an embodiment of the present disclosure in a pre-delivery state. [Figure 23] FIG. 23 is a cross-sectional view of the locking arrangement of FIG. 22. [Figure 24A] FIG. 23 is a perspective view of the arrangement shown in FIG. 22 rotated 90 degrees. [Figure 24B] 24B is a cross-sectional view taken along line YY in FIG. 24A. [Figure 24C] 24B is a cross-sectional view taken along line XX in FIG. 24A. [Figure 24D] 24B is a cross-sectional view taken along the line WW in FIG. 24A. [Figure 25A] FIG. 24B is a perspective view of the locking arrangement in FIG. 24A after initial retraction of the guard members. [Figure 25B] 25B is a cross-sectional view taken along line YY in FIG. 25A. [Figure 25C] 25B is a cross-sectional view taken along line XX in FIG. 25A. [Figure 25D] 25B is a cross-sectional view taken along the line WW in FIG. 25A. [Figure 26A] FIG. 25B is a perspective view of the locking arrangement in FIG. 25A after further retraction of the guard member. [Figure 26B] 26B is a cross-sectional view taken along line YY in FIG. 26A. [Figure 26C] FIG. 26B is a cross-sectional view taken along line XX in FIG. 26A. [Figure 26D] 26B is a cross-sectional view taken along the line WW in FIG. 26A. [Figure 27A] FIG. 25B is a perspective view of the locking arrangement of FIG. 25A in a locked state after redeployment of the guard members after drug delivery. [Figure 27B] 27B is a cross-sectional view taken along line YY in FIG. 27A. [Figure 27C] 27B is a cross-sectional view taken along line XX in FIG. 27A. [Figure 27D] 27B is a cross-sectional view taken along the line WW in FIG. 27A. [Figure 28] FIG. 1 is a side view of a guard and locking arrangement according to an embodiment of the present disclosure. [Figure 29] FIG. 29 is a perspective view of the lock of FIG. 28. [Figure 30] FIG. 10 is a perspective view of a drug delivery device according to another embodiment of the present disclosure. [Figure 31] FIG. 31 is a perspective view of the drug delivery device of FIG. 30 with the removable cap removed. [Figure 32] 31 is a different side view of the drug delivery device of FIG. 30. [Figure 33] 31 is a different side view of the drug delivery device of FIG. 30. [Figure 34A] 1 shows a cross-sectional view of a drug delivery device according to another embodiment of the present disclosure. [Figure 34B] 34B is a cross-sectional view taken along line VV in FIG. 34A. DETAILED DESCRIPTION OF THE INVENTION

[0016] The present disclosure generally relates to a user-operable drug delivery device for administering a drug or, if the patient is the user, for self-administering a drug. Various features are disclosed to facilitate safe and proper handling of the drug delivery device, including handling the drug delivery device after it has been used to deliver a payload. Such features include an indicator to inform the user that drug delivery is complete. Based on the indicator, the user can know it is safe to remove the drug delivery device from the injection site. Additionally, a lockout arrangement is disclosed to prevent unnecessary retraction of a guard covering the sharp insertion end of the delivery member in a post-delivery state. The safety features disclosed herein leverage the operation of other components included in the drug delivery device and, therefore, do not add undue complexity to the design or manufacture of the drug delivery device. These and other advantages will be apparent to those skilled in the art upon reviewing the present disclosure.

[0017] 1A-3 show multiple views of an embodiment of a drug delivery device 10 for delivering a drug, which may also be referred to herein as a medicament or pharmaceutical. The drug may be, but is not limited to, various biological agents, such as peptides, peptibodies, or antibodies. The drug may be in fluid or liquid form, although the present disclosure is not limited to a particular state. In certain liquid formulations, the drug may have a viscosity of approximately (e.g., ±10%) 1-13 centipoise (cP), approximately (e.g., ±10%) 1-30 cP, approximately (e.g., ±10%) 1-60 cP, or other suitable viscosity profile.

[0018] Various implementations and configurations of the drug delivery device 10 are possible. This embodiment of the drug delivery device 10 is configured as a single-use, disposable syringe. In other embodiments, the drug delivery device 10 may be configured as a multiple-use, reusable syringe. The drug delivery device 10 is operable for self-administration by a patient or administration by a caregiver or formally trained healthcare provider (e.g., a doctor or nurse). This embodiment of the drug delivery device 10 takes the form of an auto-injector or pen-type injector, and as such, can be held in the user's hand for the duration of drug delivery or administration.

[0019] The configuration of various components included in the drug delivery device 10 may depend on the operational state of the drug delivery device 10. The drug delivery device 10 may have a pre-delivery or storage state, a delivery or administration state, and a post-delivery state, although fewer or more states are possible. The pre-delivery state may correspond to the configuration of the drug delivery device 10 following assembly and prior to activation by a user. In some embodiments, the pre-delivery state may exist between when the drug delivery device 10 leaves the manufacturing facility and when a patient or user activates the drive mechanism of the drug delivery device 10. This includes the moment after the user removes the drug delivery device 10 from any secondary packaging and prior to positioning the drug delivery device 10 relative to an injection site. The delivery state may correspond to the configuration of the drug delivery device 10 while drug delivery is in progress. The post-delivery state may correspond to the configuration of the drug delivery device 10 after drug delivery is completed and / or when a stopper is placed in the drug reservoir at the end-of-dose position.

[0020] The drug delivery device 10 includes an outer casing or housing 12. In some embodiments, the housing 12 may be sized and dimensioned to allow a person to grasp the syringe 10 with one hand. The housing 12 may have a generally elongated shape, such as a cylindrical shape, and extend along a longitudinal axis A between a proximal end and a distal end. An opening 14 may be formed at the distal end to allow the insertion end 28 of the delivery member 16 to extend outside the housing 12. A transparent or translucent viewing window 17 may be disposed in a wall of the housing 12 to allow a user to view the internal components of the drug delivery device 10, including the drug reservoir 20. Viewing the drug reservoir 20 through the viewing window 17 may allow a user to verify that drug delivery is in progress and / or is complete. The removable cap 19 may cover the opening 14 prior to use of the drug delivery device 10 and, in some embodiments, may include a gripper 21 a configured to assist in the removal of a sterility barrier 21 (e.g., a rigid needle shield (RNS), a flexible needle shield (FNS), etc.) mounted on the insertion end 28 of the delivery member 16. The gripper 21 a may include one or more inwardly projecting barbs or arms that frictionally or otherwise mechanically engage the sterility barrier 21 to pull the sterility barrier 21 along with the removable cap 19 when a user separates the removable cap 19 from the housing 12. Thus, removing the removable cap 19 has the effect of removing the sterility barrier 21 from the delivery member 16.

[0021] In this embodiment, the housing 12 is defined by three separate, interconnected structures: a rear cover 23 at the proximal end of the drug delivery device 10; a front cover 25 at the distal end of the drug delivery device 10 and including the opening 14; and a rear housing 27 disposed between the rigidly connected rear cover 23 and front cover 25. The front cover 25 and rear housing 27 may each have a hollow and generally cylindrical or tubular shape, and the rear cover 23 may have a generally hemispherical shape or a hollow cylindrical shape with open and closed ends. In some embodiments, the rear cover 23 and rear housing 27, and any components contained therein, may be assembled together to define a rear subassembly (FIG. 2A). Meanwhile, the front cover 25 and any components contained therein may be assembled together to define a front subassembly (FIG. 2C). In some embodiments, the rear and front subassemblies are assembled independently of one another and then combined with one another and with the drug reservoir 20 to form the fully assembled drug delivery device 10. In certain such embodiments, some or all of the aforementioned stages of assembly may occur in different manufacturing facilities or environments. In alternative embodiments, the housing 12 may be constructed of a single piece such that the housing 12 is defined by a single, integral structure.

[0022] The drug storage container 20 is disposed within the interior space of the housing 12 and is configured to contain a drug 22. The drug storage container 20 may be pre-filled, for example, by a manufacturer and shipped to a location where the drug storage container 20 is mated with the rest of the drug delivery device 10. The housing 12 may be pre-loaded with the drug storage container 20 by a manufacturer, for example, or loaded with the drug storage container 20 by a user prior to use of the drug delivery device 10. The drug storage container 20 may include a rigid wall defining an interior cavity or reservoir. The wall may be made of glass or plastic. A stopper 24 may be movably disposed in the drug storage container 20 such that it can move distally along a longitudinal axis A between the proximal and distal ends of the drug storage container 20. The stopper 24 may be constructed of rubber or any other suitable material. The stopper 24 may slidably and sealingly contact the interior surface of the wall of the drug storage container 20 to prevent or inhibit leakage of the drug 22 past the stopper 24 when the stopper 24 is being moved. Distal movement of the stopper 24 expels the drug 22 from the reservoir of the drug storage container 20 into the delivery member 16. The proximal end of the drug storage container 20 can be opened to allow the plunger 26 to extend into the drug storage container 20 and push the stopper 24 distally. In this embodiment, the plunger 26 and the stopper 24 are initially spaced apart by a gap. Upon activation of the drive mechanism 30, the plunger 26 moves distally to close the gap and contact the stopper 24. Subsequent distal movement of the plunger 26 drives the stopper 24 distally. In an alternative embodiment, the stopper 24 and the plunger 26 can be coupled to one another, for example, via a threaded connection, so that they move in unison from the start of movement of the plunger 26. As shown in FIG. 8 , as the stopper 24 moves, it can continue to move distally until it contacts a proximally facing portion of the inner surface of the wall of the drug storage container 20. This position of the stopper 24 may be referred to as the end-of-dose position and may correspond to when delivery of the medication 22 to the patient is complete or substantially complete.

[0023] The delivery member 16 is connected or operable to be connected in fluid communication with a reservoir of the drug storage container 20. The distal end of the delivery member 16 may define an insertion end 28 of the delivery member 16. The insertion end 28 may include a sharpened tip or other pointed shape that enables the insertion end 28 to pierce the patient's skin 5 and subcutaneous tissue during insertion of the delivery member 16. The delivery member 16 may be hollow and have an internal flow path. One or more openings may be formed in the insertion end 28 to allow the drug to flow from the delivery member 16 into the patient.

[0024] In this embodiment, the drug storage container 20 is a pre-filled syringe and has an enclosed hollow metal needle for the delivery member 16, where the needle is fixed against the wall of the drug storage container 20 and is in permanent fluid communication with the reservoir of the drug storage container 20. In other embodiments, the drug storage container 20 may be a needleless cartridge and therefore may not initially be in fluid communication with the delivery member 16. In such embodiments, the drug storage container 20 may move toward or away from the proximal end of the delivery member 16 during operation of the drug delivery device 10 such that the proximal end of the delivery member 16 penetrates through a septum covering the opening of the drug storage container 20, thereby establishing fluid communication with the reservoir of the drug storage container 20.

[0025] The drug storage container 20 may be fixed relative to the housing 12 so that the drug storage container 20 does not move relative to the housing 12 once it is placed therein. As such, the insertion end 28 of the delivery member 16 always extends through the opening 14 of the housing 12 in the pre-delivery state, the delivery state, and the post-delivery state. In this embodiment, a container holder 31 fixes the position of the drug storage container 20 within the housing 12. The container holder 31 may have a hollow and generally cylindrical or tubular shape, and the drug storage container 20 may be partially or entirely disposed within the container holder 31. The distal end of the container holder 31 may include an inwardly protruding flange 33 that abuts against the neck of the drug storage container 20, thereby preventing distal movement of the drug storage container 20. The container holder 31 may be fixedly attached to the housing 12 so that the container holder 31 is prevented from moving relative to the housing 12 during operation of the drug delivery device 10.

[0026] In alternative embodiments, the drug reservoir 20 may be movably coupled to the housing 12 such that the drug reservoir 20 can move relative to the housing 12 during operation of the drug delivery device 10. In certain such alternative embodiments, the insertion end 28 of the delivery member 16 may be stored within the opening 14 of the housing 12 in a pre-delivery state. Thereafter, during operation of the injection device 10, the insertion end 28 of the delivery member 16 may be deployed through the opening 14 of the housing 12 for insertion into a patient. This movement may, in some embodiments, be the result of the drug reservoir 20 being driven distally relative to the housing 12.

[0027] Plunger 26 may be constructed of multiple interconnected parts or may have a one-piece configuration. In this embodiment, plunger 26 includes a rod 65 having a threaded outer surface 66 and a washer or disk 68 rigidly attached to the distal end of rod 65. Disk 68 may impact and push against stopper 24 when drive mechanism 30 is actuated. Thus, in some embodiments, disk 68 may have dampening properties that attenuate any shock or vibration associated with an impact event.

[0028] The drug delivery device 10 may further include a guard mechanism for preventing contact with the insertion end 28 of the delivery member 16 when the drug delivery device 10 is not being used to administer an injection. The guard mechanism may include a guard member 32 movably positioned at the distal end of the housing 12 adjacent the opening 14. The guard member 32 may be hollow and have a generally cylindrical or tubular shape. The guard member 32 may have a proximal end housed within the housing 12 and may be configured to move relative to the housing 12 between an extended position in which the distal end of the guard member 32 extends through the opening 14 of the housing 12 and a retracted position in which the distal end of the guard member 32 is fully or partially retracted within the opening 14 of the housing 12. At least in the extended position, the guard member 32 may extend beyond and surround the insertion end 28 of the delivery member 16. In some embodiments, the insertion end 28 of the delivery member 16 may be exposed by moving the guard member 32 toward the retracted position. Further, in some embodiments, the guard member 32 may be coupled to the housing 12 and / or vessel holder 31 via, for example, a pin and slot arrangement, such that the guard member 32 can move linearly relative to the housing 12 and / or vessel holder 31 but is prevented from rotating relative to the housing 12 and / or vessel holder 31.

[0029] The proximal and distal ends of the guard member 32 may include an activator portion 34 and a skin-contacting portion 36, respectively (FIG. 3). In some embodiments, the activator portion 34 and the skin-contacting portion 36 may be integrally formed to define a single, integrated structure. In other words, the activator portion 34 and the skin-contacting portion 36 may be constructed of a single piece. In other embodiments, the activator portion 34 and the skin-contacting portion 36 may be physically separate structures that are fixedly attached to one another so that they are fixed relative to one another and / or move in unison when moving. At least the skin-contacting portion 36 of the guard member 32 may have a hollow and generally cylindrical or tubular shape and, in some embodiments, may be centered on the longitudinal axis A of the drug delivery device 10. Movement of the guard member 32 from the extended position to the retracted position may be achieved by pressing the skin-contacting portion 36 against the patient's skin 5 at the injection site (FIGS. 6-8). In embodiments in which the delivery member 16 protrudes from the opening 14 of the housing 12 in a pre-delivery or storage state, this movement may result in insertion of the insertion end 28 of the delivery member 16 into the patient's skin 5 .

[0030] The guard mechanism may further include a guard biasing member 35. The guard biasing member 35 may bias or urge the guard 32 toward the extended position by exerting a distal biasing force on the guard member 32. A user may overcome this biasing force by pressing the guard member 32 against the injection site. When the injection is completed and the drug delivery device 10 is moved away from the injection site, the guard biasing member 35 may return the guard member 32 to the extended position, thereby covering the insertion end 28 of the delivery member 16. In some embodiments, the guard biasing member 35 may be a compression spring. Furthermore, in some embodiments, the guard biasing member 35 may be axially disposed between and in contact with both the proximally facing inner surface of the guard member 32 and the distally facing inner or outer surface of the lock 40. In embodiments in which the guard member 32 is a compression spring, movement of the guard member 32 in the proximal direction may compress the guard biasing member 35 between the guard member 32 and the lock 40. In some embodiments, the guard biasing member 35 may be partially compressed prior to retraction of the guard member 32, thereby exerting a biasing force on both the guard member 32 and the lock 40 in the pre-delivery state.

[0031] The drug delivery device 10 may further include a drive mechanism 30 disposed partially or entirely within the housing 12. Generally, the drive mechanism 30 may be configured to store energy and, upon or in response to activation of the drive mechanism 30 by a user, release or output that energy to drive the plunger 26 to expel the drug 22 from the drug reservoir 20 through the delivery member 16 and into the patient. In this embodiment, the drive mechanism 30 is configured to store mechanical potential energy; however, alternative embodiments of the drive mechanism 30 may be configured differently, for example, the drive mechanism 30 stores electrical or chemical potential energy. Upon activation of the drive mechanism 30, the drive mechanism 30 may convert the potential energy into kinetic energy to move the plunger 26.

[0032] In this embodiment, the drive mechanism 30 includes a rotary biasing member 50, a rotary biasing member housing 52, a trigger ring 54, and a mechanical linkage 56. The rotary biasing member 50 may be a torsion spring (e.g., a spiral torsion spring, a helical torsion spring, etc.) that is initially held in a biased state. In the biased state, the rotary biasing member 50 may be twisted or coiled and held in the twisted or coiled configuration by the trigger ring 54 via the mechanical linkage 56. When released, the rotary biasing member 50 attempts to return to its natural length or shape, resulting in a biasing force that rotates the mechanical linkage 56. Furthermore, the mechanical linkage 56 may convert rotational motion into linear motion to drive the plunger 26 distally. In some embodiments, the mechanical linkage 56 may convert rotational motion from the rotary biasing member 50 into linear motion to drive the plunger 26 distally and into rotational motion of the plunger 26 about the longitudinal axis A.

[0033] Alternative embodiments may utilize an energy source different from a rotary biasing member. Certain alternative embodiments may utilize, for example, a linear biasing member (e.g., a helical compression spring, a helical extension spring, etc.) that, when released, outputs a force in the direction of movement of the plunger 26. In addition to or instead of a biasing member, other embodiments may include any one or combination of an electromechanical arrangement including an electric motor and / or solenoid coupled to the plunger 26 and a drive train or transmission; or an arrangement that generates or releases pressurized gas or fluid to propel the plunger 26 or acts directly on the stopper 24 to move the stopper 24 and expel the drug 22 therefrom through the drug reservoir 20. In embodiments in which the drug reservoir 20 and / or delivery member 16 are movable relative to the housing 12, the drive mechanism 30 may, upon activation, drive the drug reservoir 20 and / or delivery member 16 distally such that the insertion end 28 of the delivery member 16 is inserted into the patient. Thus, in certain embodiments, the drive mechanism 30 may provide the driving force necessary to both insert the delivery member 16 into the patient and expel the drug 22 from the drug reservoir 20 .

[0034] 1A-3 , the mechanical linkage 56 may include a plunger guide 60 and a nut 62. The plunger guide 60 may be hollow and have a generally cylindrical or tubular shape. The proximal end of the plunger 26 may be disposed within the plunger guide 60, at least in a pre-delivery state. The proximal extension of the plunger guide 60 may extend through the center of the rotary biasing member 50 and may be coupled to the rotary biasing member 50 such that the plunger guide 60 rotates in unison with the rotary biasing member 50 when the rotary biasing member 50 is released. The inner surface of the plunger guide 60 is coupled to the outer surface of the plunger 26 to allow axial movement of the plunger 26 relative to the plunger guide 60 while the plunger 26 rotates in unison with the plunger guide 60 when the rotary biasing member 50 is released. The coupling between the plunger guide 60 and the plunger 26 may be achieved, for example, via a spline mechanism, in which a longitudinal protrusion on one of the inner surface of the plunger guide 60 or the outer surface of the plunger 26 is slidingly received in a longitudinal slot on the other of the outer surface of the plunger 26 or the inner surface of the plunger guide 60. The nut 62 may have a generally annular shape and may be disposed around the distal end of the plunger 26 in the pre-delivery state. The nut 62 may be fixedly mounted so that the nut 62 is not movable relative to the rear housing 27. Furthermore, the nut 62 may have a threaded inner surface 64 that engages the threaded outer surface 66 of the plunger 26. As a result of this threaded engagement, rotation of the plunger 26 relative to the nut 62 may linearly drive the plunger 26 distally. This, in turn, causes the plunger 26 to act on and push a stopper distally to expel the medicament 22 from the reservoir 20 to the patient via the inserted delivery member 16.

[0035] The guard member 32 may be configured to interact with the drive mechanism 30 when the guard member 32 moves from the extended position to the retracted position. This interaction may actuate the drive mechanism 30 to output the energy necessary to drive the plunger 26 to expel the drug 22 from the drug reservoir 20 and / or insert the insertion end 28 of the delivery member 16 into the patient's skin 5. In this embodiment, movement of the guard member 32 from the extended position to the retracted position releases the rotary biasing member 50 from its biased state, thereby allowing the rotary biasing member 50 to de-energize and drive the plunger 26 via the mechanical linkage 56 to expel the drug 22 from the drug reservoir 20. More specifically, in the pre-delivery state, the trigger ring 54 may be disposed in an initial position where it is in locking engagement with the outer surface of the plunger guide 60, thereby preventing rotation of the plunger guide 60 under the biasing force of the rotary biasing member 50. As a result, the rotary biasing member 50 is prevented from de-energizing. When the guard member 32 moves from the extended position to the retracted position as a result of being pressed against the patient's skin 5, the activator portion 34 of the guard member 32 pushes the trigger ring 54 proximally to a release position where the trigger ring 54 separates from the plunger guide 60. As a result, the plunger guide 60 can rotate under the biasing force of the rotary biasing member 50 and drive the plunger 26 distally via the threaded connection between the plunger 26 and the nut 62.

[0036] In alternative embodiments, the trigger ring 54 may be omitted, and the activator portion 34 of the guard member 32 may lockingly engage the outer surface of the plunger guide 60 to prevent it from rotating when the guard member 32 is in the extended position. Thus, the guard member 32 may hold the rotatable biasing member 50 in a biased state in such an embodiment. When the guard member 32 moves from the extended position to the retracted position, the activator portion 34 of the guard member 32 may disengage from the plunger guide 60, thereby releasing the plunger guide 60 to rotate under the biasing force of the biasing member 50.

[0037] The rotary biasing member housing 52 may be disposed within and rigidly attached to the housing 12. The rotary biasing member housing 52 may have a hollow and generally cylindrical or tubular shape and may fully or partially enclose the rotary biasing member 50 such that the rotary biasing member housing 52 surrounds or partially surrounds the rotary biasing member 50. The rotary biasing member housing 52 may function as a support or seat for pushing the rotary biasing member 50 out when released.

[0038] 1A-3 , the drug delivery device 10 may further include an indicator 70 operably coupled to the drive mechanism 30 that generates an audible signal. The indicator 70 may be configured to generate the audible signal continuously throughout the duration of drug delivery and to cease generating the audible signal when drug delivery is complete, such as when the stopper 24 reaches the end-of-dose position. The audible signal may indicate to the user that drug delivery has begun and / or is in progress; and cessation or absence of the audible signal may indicate to the user that drug delivery has been completed and / or that it is safe to remove the delivery member 16 from the injection site. In some embodiments, the continuous audible signal may end simultaneously with the stopper 24 reaching the end-of-dose position; while in other embodiments, the continuous audible signal may end after a short delay after the stopper 24 reaches the end-of-dose position. The continuous audible signal may include any one or combination of a plurality of discrete and repeating clicks, hums, buzzes, rings, or any other continuous sound. In some embodiments, there may be vibration or other tactile feedback associated with the continuous audible signal, although this is not required and may be desirable to mitigate or avoid in some scenarios.

[0039] The indicator 70 may be disposed within and / or rotatable relative to the housing 12. As the indicator 70 rotates, it may slide or rub against the housing 12 or a component fixed relative to the housing 12. As described in more detail below, sliding contact between the rotating indicator 70 and the housing 12 or other fixed component may generate an audible signal. In this embodiment, rotation of the indicator 70 is achieved by fixedly attaching the indicator 70 to the plunger guide 60 so that the indicator 70 rotates in unison with the plunger guide 60. Thus, when the rotary biasing member 50 is released and begins to rotate the plunger guide 60, the indicator 70 simultaneously begins to rotate and generate an audible signal. The plunger guide 60, and therefore the indicator 70, continues to rotate as the plunger 26 is driven distally to expel the medication 22 from the medication reservoir 20. When stopper 24 reaches the end-of-dose position and can no longer move distally, plunger 26 may stop moving, resulting in plunger guide 60 and indicator 70 stopping rotation. The cessation of rotation of indicator 70, in certain embodiments, causes indicator 70 to stop generating an audible signal. In alternative embodiments, indicator 70 may be directly coupled to rotary biasing member 50, instead of being indirectly coupled to rotary biasing member 50 via plunger guide 60.

[0040] According to this embodiment, in addition to providing audible feedback, the indicator 70 may be part of a damping assembly. A damping assembly generally functions as a shock absorber operable to absorb or dampen the impact or impulse caused by the plunger 26 striking the stopper 24. If unmitigated, this impulse could shatter or destroy the medication reservoir 20, which may be made of glass, and / or startle the user. The output of the rotary biasing member 50 may be at its greatest magnitude upon initial release compared to subsequent plunger strokes. As a result, the rotary biasing member 50 may accelerate the plunger 26 to a relatively high velocity before contact with the stopper 24. The damper assembly may reduce the velocity of the plunger 26 prior to contact between the plunger 26 and the stopper 24. In some embodiments, the damping effect is provided by hydraulic fluid sealed between the indicator 70 and the rear cover 23. The hydraulic fluid resists rotation of the indicator 70, thereby slowing the rotation of the plunger guide 60, at least at the beginning of the rotation. As a result, the rotary biasing member 50 de-energizes at a slower rate than if the damping assembly were omitted, and thus the plunger 26 moves at a reduced velocity before colliding with the stopper 24. In this embodiment, hydraulic fluid is at least partially disposed in an annular groove 72 ( FIG. 10 ) formed in the proximal-facing surface of the indicator 70. The annular groove 72 may receive an annular protrusion 74 ( FIG. 11 ) extending distally from the rear cover 23. The annular protrusion 74 may sealingly and slidably engage the annular groove 72 to retain hydraulic fluid in an interior space located radially inward from the annular protrusion 74. Furthermore, the annular groove 72 may be disposed radially outward from a recess 76 ( FIG. 11 ) formed in the distal-facing surface of the indicator 70. The recess 76 may receive the proximal end of the plunger guide 60, providing a fixed connection between the indicator 70 and the plunger guide 60.

[0041] Having described the general configuration and operation of the drug delivery device 10, a method for performing an injection using the drug delivery device 10 will now be described with reference to FIGS. 4-9 . As a preliminary step, the user may remove the drug delivery device 10 from any secondary packaging, such as a plastic bag and / or a cardboard box. Additionally, as a preliminary step, the user may prepare the injection site by, for example, rubbing the patient's skin 5 with an alcohol wipe. Next, as shown in FIG. 4 , the user may pull the removable cap 19 from the front cover 23 to remove it. As a result of this movement, the gripper 21 a may pull the sterility barrier 21 from the drug reservoir 20 to remove it. This may expose the insertion end 28 of the delivery member 16. Nevertheless, as shown in FIG. 4 , the insertion end 28 of the delivery member 16 will remain surrounded by the guard member 32 at this stage. The user may then place the skin-contacting portion 36 of the guard member 32 over the injection site (FIG. 3) and subsequently press the skin-contacting portion 36 against the injection site (FIG. 4). The force exerted by the user will overcome the biasing force of the guard biasing member 35, causing the guard member 32 to retract into the opening 14 moving proximally from the extended position to the retracted position (FIG. 6). The delivery member 16 remains fixed relative to the housing 12 during the retraction movement of the guard member 32.

[0042] Retraction of the guard member 32 can result in several actions. Because the delivery member 16 remains fixed relative to the housing 12 during retraction of the guard member 32, the insertion end 28 of the delivery member 16 is forced to protrude through the opening in the skin-contacting portion 36 of the guard member 32, thereby piercing the patient's skin 5 at the injection site and penetrating the patient's subcutaneous tissue. Retraction of the guard member 32 can also actuate the drive mechanism 30. More specifically, retraction of the guard member 32 can cause the activator portion 34 to push the trigger ring 54 proximally to a release position where the trigger ring 54 separates from the plunger guide 60. As a result, the plunger guide 60 can rotate under the biasing force of the rotary biasing member 50 and drive the plunger 26 in a distal linear direction via the threaded connection between the plunger 26 and the nut 62 ( FIG. 7 ). The initial movement of the plunger 26 in the distal direction can cause the plunger 26 to close the gap between the plunger 26 and the stopper 24. After contacting stopper 24, plunger 26 may push stopper 24 distally to expel drug 22 from the reservoir of drug storage container 20 into delivery member 16 and through insertion end 28 of delivery member 16 into the patient's subcutaneous tissue. Additionally, as described in more detail below, retraction of guard member 32 may rotate lock 40 toward a locked position where it prevents retraction of guard member 32 into opening 14 at a time subsequent to when guard member 32 is deployed to its extended post-injection position.

[0043] Concurrently with or shortly thereafter, the indicator 70 may begin to generate an audible signal. The audible signal may be generated continuously or substantially continuously throughout drug delivery. The audible signal informs the user that drug delivery is progressing, and in some embodiments, the user may be informed of the significance of the audible signal by instructions provided with the drug delivery device 10. In some embodiments, these instructions may take the form of an IFU pamphlet packaged with the drug delivery device 10. The user may also confirm that drug delivery is progressing by viewing the movement of the stopper 24 and / or plunger 26 through the window 17.

[0044] Drug delivery will continue until stopper 24 reaches the end-of-dose position (FIG. 8), where stopper 24 abuts against the proximally facing surface of the wall of drug reservoir 20. As a result, plunger 26 stops moving distally and plunger guide 60 stops rotating. When plunger guide 60 stops rotating, indicator 70 also stops rotating. As a result, indicator 70 stops generating an audible signal. The silencing of the audible signal may inform the user that drug delivery is complete. The user may also confirm that drug delivery is complete by viewing stopper 24 at the end-of-dose position through window 19.

[0045] The user may then remove the drug delivery device 10 from the injection site. In the absence of force applied by the user, the guard biasing member 35 extends, pushing the guard member 32 from the retracted position to the extended position (FIG. 9). This movement may cause the lock 40 to rotate into a locked position where it prevents subsequent retraction of the guard member 32. If the drug delivery device 10 is for single use, the user may thereafter discard the drug delivery device 10, for example, by placing it in a sharps container.

[0046] 10-12, embodiments of the indicator 70 will now be described in detail. The indicator 70 may be sized and dimensioned to fit within the back cover 23. The indicator 70 may have a generally annular shape, which may be centered about the longitudinal axis A of the drug delivery device 10. In this embodiment, the longitudinal axis A of the drug delivery device 10 corresponds to the axis of rotation of the indicator 70, although this need not be the case. The indicator 70 may include a central portion 80 and a peripheral portion 82 disposed radially outward from the central portion 80. The central portion 80 and the peripheral portion 82 may be integrally formed to define a single, integrated structure, or may be formed as separate but firmly connected structures. In general, the central portion 80 may be configured to couple the indicator 70 to the plunger guide 60, and the peripheral portion 82 may be configured to engage the back cover 23 to generate an audible signal during drug delivery. In an alternative embodiment, indicator 70 may be integrally formed with plunger guide 60 such that these two elements define a single, integrated structure rather than separate structures.

[0047] A recess 76 may be formed in a distally facing surface of the central portion 80 of the indicator 70. The recess 76 may have an annular cross-section and may be sized to accommodate the proximal end of the plunger guide 60. In some embodiments, one or more protrusions 86 may extend radially inward from the wall defining the recess 76. These protrusions 86 may be received in corresponding grooves or slots formed on the exterior of the plunger guide 60 to rotationally lock the plunger guide 60 and the indicator 70 so that these components rotate together during operation. In an alternative embodiment, the plunger guide 60 may have radially outward extending protrusions received in corresponding grooves or slots formed in the central portion 80 of the indicator 70.

[0048] The peripheral portion 82 of the indicator 70 may include an annular wall 88 centered about a longitudinal axis A and a plurality of flexible, arm-like protrusions 90 each extending generally radially outward from the outer surface of the annular wall 88. In this embodiment, the protrusions 90 may be spaced regularly around the circumference of the annular wall 88; however, alternative embodiments may space the protrusions 90 irregularly around the circumference of the annular wall 88 depending on the desired acoustic profile of the audio signal. Some or all of the protrusions 90 may lie along a common plane perpendicular to the longitudinal axis A. With reference to FIG. 12 , when viewed along the longitudinal axis A, each protrusion 90 may have a generally S-shaped profile. The radially innermost and radially outermost portions of the protrusions 90 may each extend radially or substantially radially relative to the longitudinal axis A. An intermediate portion of protrusion 90 located radially between and connecting the radially innermost portion of protrusion 90 and the radially outermost portion of protrusion 90 may be disposed perpendicular or substantially perpendicular to one or both of the radially innermost portion of protrusion 90 and the radially outermost portion of protrusion 90. The radially outermost portion of each protrusion 90 may define a free end 92 of protrusion 90.

[0049] As shown in FIG. 12 , the free end 92 of each of the protrusions 90 may be in sliding contact with the inner surface 94 of the rear cover 23. A plurality of ramp-like protrusions 96 may each generally extend radially inward from the inner surface 94 of the rear cover 23 toward the display 70. For clarity, only some of the protrusions 96 are identified by reference numbers and callouts in the drawings. The protrusions 96 may be spaced at regular or irregular intervals around the inner surface 94 of the rear cover 23. The protrusions 90 and 96 may be concentrically arranged with respect to one another, with each group of protrusions centered on a longitudinal axis. Furthermore, the protrusions 96 may be located in the same plane as the protrusions 96. In this embodiment, the protrusions 96 are arranged radially outward from the protrusion 90 such that the protrusions 96 are arranged in a circular fashion around the protrusion 90. However, in alternative embodiments, the positions of the protrusions 90 and 96 may be switched, such that the protrusions 90 are arranged in a circular fashion around the protrusion 96.

[0050] In FIG. 12 , the indicator 70 rotates clockwise during drug delivery. The rear cover 23 remains fixed during the rotation of the indicator 70. As a result, the free end 92 of each of the protrusions 90 slides along the inner surface 94 of the rear cover 23, and because the protrusions 90 lie in the same plane as the protrusions 96, the free end 92 of each of the protrusions 90 contacts the protrusions 96 one by one. Each of the protrusions 90 may be configured to elastically deform, bend, deflect, etc., in an inward radial direction such that each time the free end 92 of the protrusion 90 encounters one of the protrusions 96, the protrusion 90 momentarily moves from an outer radial position to an inner radial position. Once the free end 92 slides over and passes the protrusions 96, the protrusion 90 may elastically return to the outer radial position. In some embodiments, in a pre-delivery state before rotation of indicator 70, some or all of free end 92 may contact inner surface 95 of rear cover 23 such that free end 92 is in an undeflected state, which may reduce the likelihood that the resiliency of protrusion 90 will be compromised in the period between manufacture and use.

[0051] An audible signal may be generated as a result of the interaction between protrusions 90 and protrusions 96. In some embodiments, an audible signal may be generated as a result of one of the protrusions 90 snapping back to its outer radial position after the free end 92 of the protrusion 90 passes over one of the protrusions 96. This snapping action may occur rapidly, resulting in the free end 92 impacting the inner surface 94 of the rear cover 23 with substantial force. This impact event may then generate an audible clicking sound. Additionally or alternatively, the free end 92 may generate a sound when it first contacts one of the protrusions 96 and / or while it slides over one of the protrusions 96.

[0052] Repeated contact between the prongs 90 and the prongs 96 during rotation of the indicator 70 produces multiple clicks. In some embodiments, each distinct click may be perceptible to the user. In other embodiments, the amount of time between each click may be very short, such that the multiple clicks are perceived by the user as a humming sound. The frequency of the clicks may depend on the number of selected prongs 90, the number of selected prongs 96, and / or the selected rotation speed of the indicator 70. Several different embodiments of indicators 70 are shown in Figures 13, 16, and 17, including six prongs 90, eight prongs 90, and twelve prongs 90, respectively.

[0053] In some embodiments, two, three, four, five, or more pairs of protrusions 90 and 96 may synchronously engage with one another during rotation of the indicator 70. A louder clicking sound may be generated for each additional set of protrusions 90 and 96 that synchronously engage with one another. In alternative embodiments, only one pair of protrusions 90 and 96 (i.e., one protrusion 90 and one protrusion 96) may engage with one another at any given time during rotation of the indicator 70. In such alternative embodiments, the clicking sound may be less loud than in embodiments in which multiple pairs of protrusions 90 and 96 synchronously engage with one another.

[0054] Various different combinations of protrusions 90 and 96 and synchronous pairs are possible depending on the desired frequency and amplitude of the audible signal. In some embodiments, an arrangement includes six protrusions 90 and nine protrusions 96, with three pairs of protrusions 90 and 96 synchronously engaging each other. This arrangement may result in nine separate clicks per rotation of the indicator 70. In other embodiments, an arrangement includes eight protrusions 90 and fifty protrusions 96, with two pairs of protrusions 90 and 96 synchronously engaging each other. This arrangement may result in 200 separate clicks per rotation of the indicator 70. In yet a further embodiment, an arrangement includes six protrusions 90 and sixteen protrusions 96, with two pairs of protrusions 90 and 96 synchronously engaging each other. This arrangement, shown in FIG. 12, may result in 48 separate clicks per rotation of the indicator 70.

[0055] Another design factor that can be varied to achieve a desired acoustic profile of the audible signal is the arc length of each of the protrusions 90. The vibrations experienced by the protrusions 90 as they slide over one of the protrusions 96 may depend on the arc length of the protrusions 90, which may in turn affect the sound produced by the protrusions 90. Additionally, the speed at which the protrusions 90 snap back to their outer radial position and impact the inner surface 94 of the rear cover 23 after passing over one of the protrusions 96 may depend on the arc length of the protrusions 90. Figures 13-15 illustrate protrusions 90 with progressively longer arc lengths, thus increasing the magnitude of their arc dimension relative to the longitudinal axis A. In Figure 13, the arc dimension α1 of each protrusion 90 is approximately 35 degrees (e.g., ±10%). In Figure 14, the arc dimension α2 of each protrusion 90 is approximately 40 degrees (e.g., ±10%). In FIG. 15, the arc dimension α3 of each protrusion 90 is approximately (eg, ±10%) 45 degrees.

[0056] An additional design factor that can be varied to achieve a desired acoustic profile of the audible signal is the width W1 of each of the protrusions 96. As shown in FIG. 11 , width W1 corresponds to the distance measured in the direction of longitudinal axis A between the proximal and distal ends of the protrusions 90. A larger width W1 generally results in a louder click due to an increased surface area of ​​the protrusions 90 contacting the rear cover 23. In some embodiments, W1 can be approximately equal to (e.g., ±10%) 2.0 mm, or approximately equal to (e.g., ±10%) 2.5 mm, or approximately within (e.g., ±10%) the range of 2.0-2.5 mm, or approximately (e.g., ±10%) 5.0 mm or less, or approximately (e.g., ±10%) 4.0 mm or less, or approximately (e.g., ±10%) 3.0 mm or less.

[0057] A further design factor that can be varied to achieve a desired acoustic profile of the audible signal relates to the shape of the protrusions 96. As shown in FIGS. 18-21 , each of the protrusions 96 has a height H1 that corresponds to the distance the protrusion 96 extends radially away from the inner surface 94 of the rear cover 23 toward the longitudinal axis A. In some embodiments, the height H1 can be approximately equal to (e.g., ±10%) 0.2 mm, or approximately equal to (e.g., ±10%) 0.3 mm, or approximately (e.g., ±10%) within a range between 0.2 and 0.3 mm, or approximately (e.g., ±10%) 1.0 mm or less, or approximately (e.g., ±10%) 0.5 mm or less, or approximately (e.g., ±10%) 0.4 mm or less. In the embodiment shown in FIGS. 18 and 19 , the protrusions 96 can each have a height H1 approximately equal to (e.g., ±10%) 0.2 mm, and the indicator can include 12 protrusions 90. In the embodiment shown in Figures 20 and 21, the protrusions 96 may each have a height H1 in the range of approximately (e.g., ±10%) between 0.2 and 0.3, and the indicator may include eight protrusions 90.

[0058] The respective slopes of the leading surface 97 and trailing surface 99 of each protrusion 96 can also affect the acoustic profile of the audible signal. The leading surface 97 of a protrusion 96 can be the surface that first contacts the free end 92 of the protrusion 90 as the free end 92 slides over the protrusion 96. The trailing surface 99 can be the surface of the protrusion 96 opposite the leading surface 97. In the embodiment shown in FIGS. 18 and 19, the protrusion 96 has a generally triangular shape when viewed along the longitudinal axis A, and the angle of slope of the leading surface 97 is equal to or substantially equal to the angle of slope of the trailing surface 99. In the embodiment shown in FIGS. 20 and 21, the protrusion 96 also has a generally triangular shape when viewed along the longitudinal axis A. However, in this embodiment, the angle of slope of the leading surface 97 is less than the angle of slope of the trailing surface 99. The angle of slope of the leading surface 97 can be less than 90 degrees, while the angle of slope of the trailing surface 99 can be 90 degrees or greater. As a result, the free ends of the protrusions 96 do not slide down the trailing surface 99, but rather snap past the tips of the unobstructed protrusions 96. Compared to the embodiment of Figures 18 and 19, in which the free ends 92 of the protrusions 90 slide down the trailing surface 99 and may thereby be subjected to frictional forces, the free ends 92 in the embodiment of Figures 20 and 21 may accelerate faster as they snap back, thereby producing a louder and / or more distinct clicking sound.

[0059] As described above, at the start of drug delivery, the indicator 70 will begin to rotate relative to the rear cover 23, and the protrusion 90 will begin to rub against the protrusion 96, generating an audible signal. The audible signal will continue continuously throughout drug delivery. When drug delivery is complete, the indicator 70 may stop rotating, thereby ceasing the audible signal. The cessation or silencing of the audible signal notifies the user that drug delivery is complete. After confirming that drug delivery is complete, the user may lift the drug delivery device 10 from the injection site. As a result of this movement, the guard member 32 may deploy to the extended position, covering the insertion end 28 of the delivery member 16. To ensure that the guard member 32 does not retract to expose the used delivery member 16, the drug delivery device 10 may include a lockout arrangement, described below in connection with FIGS. 22-27D.

[0060] The lockout arrangement includes components having functions unrelated to the locking function, such as the lock 40 and the container holder 31. Generally, the lock 40 is configured to selectively rotate depending on the axial position of the guard member 32 to lock the guard member 32 in the extended position once the guard member 32 has moved from the retracted position to the extended position. Referring to FIGS. 22 and 23 , the lock 40 may have a hollow and generally tubular or annular shape and may be centered about a longitudinal axis A. In this embodiment, the longitudinal axis A of the drug delivery device 10 corresponds to the axis of rotation of the lock 40, but this need not be the case. The proximal end of the lock 40 may be in direct contact with the container holder 31, and the distal end of the lock 40 may be at least partially disposed within the guard member 32. The guard biasing member 35 may be axially disposed between a distal-facing surface of the lock 40 and a proximal-facing surface of the guard member 32. The guard bias member 35 may be initially in a compressed or biased state such that it exerts a biasing force that urges the lock 40 and the guard member 32 apart. This biasing force may urge the guard member 32 toward the extended position and urge the proximal end of the lock 40 against the vessel holder 31.

[0061] Rotation of the lock 40 is accomplished by a camming arrangement between the lock 40 and the vessel holder 31. More specifically, with reference to FIG. 23 , the proximal end of the lock 40 may include one or more camming surfaces 100 configured to slidably engage one or more corresponding camming surfaces 102 included on the distal end of the vessel holder 31. In some embodiments, the camming surfaces 100 on the lock 40 may have a generally sawtooth appearance when viewed radially from the longitudinal axis A. Furthermore, the camming surfaces 100 may be arranged about the longitudinal axis A such that each camming surface 100 is located at a different angular position about the longitudinal axis A. Similarly, the camming surfaces 102 on the vessel holder 31 may have a generally sawtooth appearance when viewed radially from the longitudinal axis A. Furthermore, the camming surfaces 102 may be arranged about the longitudinal axis A such that each camming surface 102 is located at a different angular position about the longitudinal axis A.

[0062] When pressed against each other, the cam surfaces 100 and 102 may translate linear motion into a combination of rotational and linear motion. More specifically, as the lock 40 moves proximally along the longitudinal axis A, each of the cam surfaces 100 may slide against a corresponding one of the cam surfaces 102. This interaction may translate the proximal linear motion of the lock 40 into a combination of rotational motion of the lock 40 about the longitudinal axis A and proximal linear motion of the lock 40. Throughout the movement of the lock 40, the container holder 31 remains fixed relative to the housing 12. Configured in this manner, the container holder 31 functions as a cam and the lock 40 functions as a cam follower. In an alternative embodiment, the housing 12 may function as a cam instead of the container holder 31. In such an alternative embodiment, the interior wall of the housing 12 may include the cam surface 102. Here, the inner wall of the housing 12 may have an annular shape centered on the longitudinal axis A and may cantilever radially inward from the outer wall of the housing 12 such that an annular gap exists between the inner and outer walls. This configuration may allow the guard member 32 to move into the annular gap between the inner and outer walls during retraction.

[0063] In this embodiment, the biasing force of the guard member 32 may continuously press the cam surface 100 of the lock 40 against the cam surface 102 of the container holder 31. As a result, the lock 40 is continuously urged to rotate about the longitudinal axis A. However, the lock 40 may not rotate depending on the relative positions of the various mounting structures included on the lock 40 and the guard member 32. As shown in FIGS. 24A-27D, the proximal end of the lock 40 may include one or more proximal protrusions 110a extending radially outward from the outer surface of the lock 40. The distal end of the lock 40 may include one or more distal protrusions 112a extending radially outward from the outer surface of the lock 40. Each of the distal protrusions 112a may be distal to each of the proximal protrusions 110a. Similarly, the proximal end of the guard member 32 may include one or more proximal protrusions 110b extending radially inward from the inner surface of the guard member 32. The distal end of guard member 32 may include one or more distal protrusions 112b extending radially inward from the inner surface of guard member 32. As described below, depending on the axial position of guard member 32 relative to lock 40, proximal protrusions 110a and 110b may abut one another to prevent rotation of lock 40 relative to guard member 32, or distal protrusions 112a and 112b may abut one another to prevent rotation of lock 40 relative to guard member 32. Guard member 32 is shown as translucent in Figures 22, 24A, 25A, 26A, and 27A for clarity, but need not actually be so.

[0064] 22-24D show various views of the lockout configuration in the pre-delivery state. Here, the guard member 32 is positioned in the extended position and is biased toward the extended position by the guard biasing member 35. The guard biasing member 35 also presses the cam surface 100 of the lock 40 against the cam surface 102 of the container holder 31, urging the lock 40 to rotate counterclockwise in FIGS. 24B-24D. However, the lock 40 is prevented from rotating because the proximal projection 110a of the lock 40 abuts the proximal projection 110b of the guard member 32 (FIG. 24B). This is because the proximal projections 110a and 110b lie in a common plane perpendicular to the longitudinal axis A in this state. Thus, the lock 40 is held by the guard member 32 in its initial rotated position in the pre-delivery state before the guard member 32 is retracted. Additionally, as shown in FIGS. 24C and 24D, distal protrusion 112a on lock 40 can be proximal to distal protrusion 112b on guard member 32 in the pre-retracted, pre-delivery state of guard member 32.

[0065] 25A-25D show the configuration immediately after guard member 32 has been pressed against the patient's skin at the injection site. Here, guard member 32 has moved proximally away from the extended position but has not yet reached the retracted position. Proximal movement of guard member 32 causes proximal protrusion 110b to slide out of contact with proximal protrusion 110a. This allows proximal protrusion 110a to rotate beyond the position previously occupied by proximal protrusion 110b, temporarily releasing lock 40 for rotation. As shown in FIG. 25C, lock 40 rotates until distal protrusion 112a contacts distal protrusion 112b. Because guard 32 has moved proximally, distal protrusion 112b may now occupy the same plane as distal protrusion 112a. Engagement of distal protrusions 112a and 112b further stops rotation of lock 40. This position of lock 40 may be referred to as the intermediate rotation position.

[0066] 26A-26D show that guard member 32 continues to move proximally as it is pushed against the injection site until it reaches the retracted position. Distal protrusion 112b slidably engages distal protrusion 112a while distal protrusion 112b moves proximally. However, distal protrusion 112a cannot rotate past distal protrusion 112b, thereby retaining lock 40 at an intermediate rotational position. As described above, guard member 32 may activate drive mechanism 30, thereby initiating drug delivery, upon reaching, or in the process of reaching, the retracted position.

[0067] Once drug delivery is complete and the user confirms this by hearing the audible signal cease, the user may remove the drug delivery device 10 from the injection site. With no resistance, the guard biasing member 35 extends, pushing the guard member 32 to the extended position shown in FIG. 27A. This movement causes distal protrusion 112b to slidably engage distal protrusion 112a until distal protrusion 112b finally slides out of engagement with distal protrusion 112a. This allows distal protrusion 112a to rotate beyond the position previously occupied by distal protrusion 112b, thereby releasing lock 40 to rotate. Lock 40 rotates until cam surfaces 100 and 102 fully engage one another, after which lock 40 stops rotating and is unable to rotate further. FIGS. 27B-27D show lock 40 reaching its final rotated position.

[0068] In the final rotated position, the lock 40 may be configured to limit (e.g., impede or prevent) proximal movement of the guard member 32. This is because, in the final rotated position, each of the distal protrusions 112a on the lock 40 may be rotationally aligned with, but axially offset from, a corresponding one of the distal protrusions 112b on the guard member 32. As such, the distal-facing mounting surface 114a of each of the distal protrusions 112a may be disposed opposite a corresponding proximal-facing mounting surface 114b of one of the distal protrusions 112b. The distal-facing mounting surface 114a may contact the proximal-facing mounting surface 114b or may be separated by a small distance (e.g., a few millimeters or less). Thus, any attempted proximal movement of the guard member 32 is prevented because the proximal-facing cradle surface 114b of each of the distal projections 112b will be stopped from moving in the proximal direction by the corresponding distal-facing cradle surface 114a of one of the distal projections 112a. Configured in this manner, the lock 40 in its final rotated position locks the guard member 32 in the extended position, thus reducing the possibility of accidental contact with the insertion end 28 of the delivery member 16 and / or reuse of the drug delivery device 10.

[0069] It should be apparent from the foregoing that the functionality of locking the guard is dependent on the rotational position of the lock 40. Therefore, assembling the drug delivery device 10 so that the lock 40 starts in an initial rotational position may be necessary to ensure proper function of the lock 40. In some embodiments, the lock 40 may be positioned within the guard member 32 prior to installation of the guard member 32 within the housing 12 of the drug delivery device 10. As a result, adjusting the rotational position of the lock 40 after the lock 40 is installed with the guard member 32 inside the drug delivery device 10 may not be feasible. Therefore, it may be desirable to verify that the lock 40 is properly oriented within the guard member 32 before installing the combined lock and guard arrangement within the drug delivery device 10. To assist in this verification process, the guard member 32 and / or the lock 40 may incorporate various adjustment features. FIGS. 28 and 29 illustrate embodiments of the guard member 32 and lock 40 that include such adjustment features.

[0070] 28 and 29 , opening 45 may be formed in the longitudinally extending wall of guard member 32, and opening 47 may be formed in the longitudinally extending wall of lock 40. As seen in FIG. 28 , opening 45 may be rotationally aligned with opening 47 when lock 40 is properly installed within guard member 32. A radially extending passage may be defined by openings 45 and 47 when lock 40 is properly installed within guard member 32. If openings 45 and 47 are rotationally aligned with each other, it may be ensured that lock 40 will occupy the initial rotational position described above when the combined guard and lock arrangement is later installed within drug delivery device 10. After an injection is performed using drug delivery device 10 and lock 40 is rotated to the final rotational position described above, openings 45 and 47 may no longer be rotationally aligned with each other.

[0071] 28 may include positioning lock 40 within guard member 32 and, if necessary, rotating lock 40 relative to guard member 32 until openings 45 and 47 are rotationally aligned with one another. In some embodiments, determining whether openings 45 and 47 are rotationally aligned with one another may include emitting light through one of openings 45 and 47 and determining, for example, via a photodetector or camera, whether the light passes through the other of openings 45 and 47. If light passes, lock 40 may be considered properly positioned within guard member 32 and installation of the combined arrangement within drug delivery device 10 may proceed. If not, lock 40 may be adjusted until openings 45 and 47 are rotationally aligned, or, if this is not possible, the combined arrangement may be discarded and a new one obtained.

[0072] A variety of external form factors are possible for the drug delivery devices described herein, depending, for example, on the needs and / or preferences of the user and / or manufacturer. Figures 30-33 show an embodiment of a drug delivery device 110 having the same or similar internal components as drug delivery device 10 described above, but having different external form factors. Elements of drug delivery device 110 that are similar in function to those included in drug delivery device 10 are assigned the same reference numerals, except increased by 100.

[0073] The drug delivery device 110 includes an outer casing or housing 112 having a generally elongated shape extending along a longitudinal axis. At most or all locations along the longitudinal axis, the housing 112 may have a circular cross-section such that the housing 112 has a substantially cylindrical shape. A recess having a transparent or translucent viewing window 117 may be disposed in a wall of the housing 112 to allow a user to view the internal components of the drug delivery device 110, including, for example, a drug reservoir. At the distal end of the housing 112, a removable cap 119 may cover an opening in the housing 112. As described above, the interior of the removable cap 119 may include a gripper configured to assist in the removal of a sterility barrier (e.g., a rigid needle shield (RNS), a flexible needle shield (FNS), etc.) from a delivery member such as a syringe needle when the removable cap 119 is removed from the housing 112. The housing 112 and removable cap 119 may each have a plurality of ribs 104 and 107 formed on their outer surfaces to improve a user's grip when separating these components. Each of the ribs may extend entirely or partially around the circumference of the housing 112 or removable cap 119.

[0074] The circular cross-section of the housing 112 can make it prone to rolling across a surface when placed on its side. To prevent or impede such rolling, part or all of the removable cap 119 can have a non-circular cross-section. In the embodiment shown in FIGS. 30-34 , the removable cap 119 has a distal end having a non-circular cross-section and a proximal end having a circular cross-section. As such, the cross-section of the removable cap 119 generally transitions from a circular cross-section to a non-circular cross-section when moving from the proximal end of the removable cap 119 to the distal end of the removable cap 119. In the embodiment shown, the non-circular cross-section of the distal end of the removable cap 119 is generally square-shaped. In other embodiments, the non-circular cross-section can be rectangular, triangular, or any other polygonal or partially polygonal shape, such that one or more long sides of the removable cap 119 are flat or substantially flat to prevent or impede rolling. Additionally, the non-circular cross-section of the distal end of removable cap 119 may gradually increase in size moving distally, such that the most distal portion of the distal end of removable cap 119 has a larger cross-sectional area than the most proximal portion of the distal end of removable cap 119. This configuration may provide a flared shape to the distal end of removable cap 119, which may aid in a user's grip and in pulling removable cap 119 away from housing 112.

[0075] In some embodiments, the housing 112 and the removable cap 119 may each include respective rotational restraint portions. These rotational restraint portions may engage with one another to prevent or inhibit rotation of the removable cap 119 relative to the housing 112 when the removable cap 119 is in a storage position, such as that shown in FIG. 30 . In some embodiments, the rotational restraint portion of the housing 112 may be adjacent to and aligned or substantially aligned with the rotational restraint portion of the removable cap 119 when the removable cap 119 is in the storage position. In the embodiment shown in FIGS. 30-33 , the rotational restraint portion of the removable cap 119 is provided by an opening 108 formed in the tubular wall of the removable cap 119 at the proximal end of the removable cap 119; the rotational restraint portion of the housing 112 is provided by an axial protrusion 109 extending distally from the distal end of the housing 112. The opening 108 can be sized to interlockingly accommodate the axial protrusion 109 when the removable cap 119 is in the storage position. As a result of this interlocking engagement, the removable cap 119 may not be able to rotate relative to the housing 112. This can be advantageous if a user twists the removable cap 119 when pulling it off the housing 112. In certain cases, rotation of the removable cap 119 can rotate a sterility barrier, such as an RNS or FNS, causing the tip of a needle to pierce a seal within the RNS or FNS. Therefore, having the axial protrusion 109 positioned within the opening 108, at least during the initial moments of cap removal, can prevent needle coring. In an alternative embodiment, the opening 108 can be formed in a wall of the housing 112, and the axial protrusion 109 can extend proximally from the proximal end of the removable cap 119.

[0076] Figures 34A and 34B show another embodiment of drug delivery device 210. Various elements of drug delivery device 210 may be similar in function and / or structure to elements of the drug delivery devices described above in connection with Figures 1-33. Such elements are assigned the same reference numerals used in Figures 1-33 except increased by 100 or multiples thereof. Structural and / or functional details that distinguish drug delivery device 210 from the drug delivery devices described above are the focus of the following discussion. Although they may not be shown in Figures 34A and 34B, components of the drug delivery devices shown in Figures 1-33, or variants of these components, may be included in drug delivery device 210, so long as the design of drug delivery device 210 does not preclude the inclusion of these components or variants thereof.

[0077] Similar to the drug delivery device 10 described above, the drug delivery device 210 may include, in part: a housing 212 having an opening 214; a drug storage container 220 including a delivery member 216 having an insertion end 228; a distally movable plunger 226 that expels a drug from the drug storage container 220 through the delivery member 216; a plunger guide 260 that surrounds at least a proximal end of the plunger 226 in a pre-delivery or storage state; a rotary biasing member 250 configured to be initially held in a biased state and to rotate about a longitudinal axis A when released; and a mechanical linkage 256 operably coupled to the plunger 226 and the rotary biasing member 250. The mechanical linkage 256 may be configured to translate rotation resulting from release of the rotary biasing member 250 into distal movement of the plunger 226. As an example, as seen in FIG. 34A , the mechanical linkage 256 may include a nut 262 that surrounds a portion of the plunger 226. As a more specific example, nut 262 may have a threaded inner surface 264 that threadingly engages a threaded outer surface 266 of plunger 226. Furthermore, nut 262 may be configured to rotate as a result of release of rotary biasing member 250. By way of example, nut 262 may be fixedly attached to the distal end of rotary biasing member 250 such that nut 262 rotates in unison with rotary biasing member 250 upon release of rotary biasing member 250. Due to the threaded coupling between nut 262 and plunger 226, rotation of nut 262 may linearly move plunger 226 distally along longitudinal axis A. As a result, plunger 226 may drive stopper 224 to displace drug from drug reservoir 220 through delivery member 216.

[0078] Unlike drug delivery device 10, mechanical linkage 256 may not rotate plunger 226, but may instead move plunger 226 distally. As an example, nut 262 of mechanical linkage 256 may rotate under the biasing force of rotary biasing member 250, and this rotation may be fully or substantially fully translated into distal movement of plunger 226 by a threaded connection between nut 262 and plunger 226. In some embodiments, a bearing may be disposed between the distal end of plunger 226 and the proximal end of stopper 224 such that rotating plunger 226 can push stopper 224 distally without rotating stopper 224.

[0079] The plunger guide 260 may serve as a seat for the proximal end of the rotary biasing member 250. As one example, the proximal end of the rotary biasing member 250 may be disposed within and fixedly attached to the plunger guide 260, as shown in FIG. 34A . The plunger guide 260 may be coupled to the housing 212 such that the plunger guide 260 is prevented from rotating and / or moving relative to the housing 212. As one example, a spline connection may be formed between an outer surface of the plunger guide 260 and an inner surface of the housing 212 to prevent relative rotation between the plunger guide 260 and the housing 212, and in some embodiments, may allow relative axial movement between the plunger guide 260 and the housing 212.

[0080] Prior to delivery or in a storage state, the nut 262 and / or another component of the mechanical linkage 256 may be prevented from rotating. As an example, the drug delivery device 210 may include a lock 254 configured to selectively prevent rotation of the nut 262. As a more specific example, the lock 254 may have an initial position (as seen in FIG. 34A ) in which the lock 254 prevents rotation of the nut 262 and a second position in which the lock 254 does not prevent rotation of the nut 262. In some embodiments, the lock 254 may have a ring or other annular shape and may surround the nut 262 in the initial position. In some embodiments, the lock 254 may move proximally when moving from the initial position to the second position. In some embodiments, the lock 272 is operably coupled to the guard member 232 such that movement of the guard member 232 from the extended position to the retracted position causes the lock 254 to move from the initial position to the second position, thereby allowing the nut 262 to rotate under the biasing force of the rotary biasing member 250 and via the threaded connection to drive the plunger 226 distally.

[0081] The drug storage container 220 may be fixedly attached to the housing 212 such that the drug storage container 220 does not move relative to the housing 212 during actuation of the drug delivery device 210. As an example, the drug delivery device 210 may include a container holder 231 having an inner end that connects to a radially outwardly extending flange at the proximal end of the drug storage container 220 and an outer end that is fixedly attached to the housing 212, as seen in FIG. 34A . The container holder 231 may have a generally annular shape. As shown in FIG. 34B , the outer end of the container holder 231 may have one or more axially extending passages or slots 231 a to allow the axially extending arms of the activator portion 234 of the guard member 232 to pass through the container holder 231.

[0082] According to some embodiments, the drug delivery device 210 may operate as follows. Initially (e.g., before delivery or in a storage state), the lock 254 may be disposed in its initial position such that the lock 254 prevents rotation of the nut 262 and, consequently, deactivation of the rotary biasing member 250. The user may then press the distal end or skin-contacting portion 236 of the guard member 232 against the skin at the injection site, causing the guard member 232 to retract into the housing 212 and move from the extended position to the retracted position. As a result of this movement, the guard member 232 may push the lock 254 distally, causing the lock 254 to move from the initial position to the second position. In the second position, the lock 254 may disengage from the nut 262, allowing the nut 262 to rotate under the biasing force of the rotary biasing member 250. Due to the threaded connection between nut 262 and plunger 226, rotation of nut 262 may move plunger 226 distally. In some embodiments, plunger 226 may not rotate but may move distally. Plunger 226 contacts stopper 224, subsequently moving stopper 224 through drug reservoir 220 and expelling the drug from drug reservoir 220 via delivery member 216.

[0083] From the foregoing, it can be seen that the present disclosure advantageously provides an improved drug delivery device that facilitates safe handling of the device in a post-delivery state, reduces the likelihood of incomplete dosing, and provides other benefits and advantages.

[0084] It will be understood that devices and methods according to the present disclosure may have one or more advantages over the prior art, any one or more of which may be present in a particular embodiment in accordance with the features of the present disclosure included in that embodiment, and other advantages not specifically recited herein may be recognized as well.

[0085] The above description describes various devices, assemblies, components, subsystems, and methods of use related to drug delivery devices. The devices, assemblies, components, subsystems, methods, or drug delivery devices may further include or be used in conjunction with drugs, including, but not limited to, the drugs identified below and their generic and biosimilar equivalents. As used herein, the term drug can be used interchangeably with other similar terms and can refer to any type of medicinal or therapeutic material, including traditional and non-traditional pharmaceuticals, nutraceuticals, supplements, biologics, biologically active agents and compositions, large molecules, biosimilars, bioequivalents, therapeutic antibodies, polypeptides, proteins, small molecules, and generic drugs. Non-therapeutic injectable materials are also encompassed. Drugs may be in liquid form, lyophilized form, or reconstituted from lyophilized form. The following list of exemplary drugs should not be considered exhaustive or limiting.

[0086] The drug will be contained in a reservoir. In some cases, the reservoir is a primary container that is either filled or pre-filled with the drug for treatment. The primary container can be a vial, cartridge, or pre-filled syringe.

[0087] In some embodiments, the reservoir of the drug delivery device may be loaded with, or the device may be used in conjunction with, a colony-stimulating factor such as granulocyte colony-stimulating factor (G-CSF). Such G-CSF agents include, but are not limited to, Neulasta® (pegfilgrastim, PEGylated filgastim, PEGylated G-CSF, PEGylated hu-Met-G-CSF) and Neupogen® (filgrastim, G-CSF, hu-Met-G-CSF), UDENYCA® (pegfilgrastim-cbqv), Ziextenzo® (LA-EP2006; pegfilgrastim-bmez), or FULPHILA (pegfilgrastim-bmez).

[0088] In other embodiments, the drug delivery device may contain or be used with an erythropoiesis-stimulating agent (ESA), which may be in liquid or lyophilized form. An ESA is any molecule that stimulates erythropoiesis. In some embodiments, the ESA is an erythropoiesis-stimulating protein. As used herein, "erythropoiesis-stimulating protein" refers to any protein that directly or indirectly causes activation of the erythropoietin receptor, for example, by binding to the receptor and causing receptor dimerization. Erythropoiesis-stimulating proteins include erythropoietin and variants, analogs, or derivatives thereof that bind to and activate the erythropoietin receptor, antibodies that bind to and activate the erythropoietin receptor, or peptides that bind to and activate the erythropoietin receptor. Erythropoiesis-stimulating proteins include Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methoxypolyethylene glycol-epoetin beta), Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), and Binocrit® (epoetin alfa). Epoetin alpha, epoetin beta, epoetin iota, epoetin omega, epoetin delta, epoetin zeta, epoetin theta, and epoetin delta, PEGylated erythropoietin, carbamylated erythropoietin, and molecules or variants or analogs thereof.

[0089] Among certain exemplary proteins are the specific proteins described below, including fusions, fragments, analogs, variants, or derivatives thereof: OPGL-specific antibodies (also referred to as RANKL-specific antibodies, peptibodies, etc.), peptibodies, related proteins, etc., including fully humanized and human OPGL-specific antibodies, particularly fully humanized monoclonal antibodies; myostatin-binding proteins, peptibodies, related proteins, etc., including myostatin-specific peptibodies; IL-4 receptor-specific antibodies, peptibodies, related proteins, etc., which particularly inhibit activities mediated by binding of IL-4 and / or IL-13 to their receptors; Interleukin 1-receptor 1 ("IL1-R1")-specific antibodies, peptibodies, related proteins, etc.; Ang2-specific antibodies, peptibodies, related proteins, etc.; NGF-specific antibodies, peptibodies, related proteins, etc.; CD22-specific antibodies, peptibodies, related proteins, etc., particularly dimers of human-mouse monoclonal hLL2 gamma chain disulfide linked to human-mouse monoclonal hLL2 kappa chain, e.g., epratuzumab (CAS Registry Number 501423-23-0 human CD22-specific antibodies, such as, but not limited to, humanized and fully human antibodies, including, but not limited to, humanized and fully human monoclonal antibodies, particularly including, but not limited to, human CD22-specific IgG antibodies, such as the human CD22-specific fully humanized antibody of (IgA); IGF-1 receptor-specific antibodies, peptibodies, and related proteins, such as, but not limited to, anti-IGF-1R antibodies; B-7-related protein 1-specific antibodies, peptibodies, and related proteins, including, but not limited to, those that inhibit the interaction of B7RP-1 with its natural receptor, ICOS, on activated T cells, including, but not limited to, a B7RP-specific fully human monoclonal IgG2 antibody, including, but not limited to, a fully human IgG2 monoclonal antibody that binds to an epitope in the first immunoglobulin-like domain of B7RP-1 (also referred to as "B7RP-1" and B7H2, ICOSL, B7h, and CD275); HuMax, e.g., 145c7; IL-15 specific antibodies, peptibodies, related proteins, etc., including but not limited to IL-15 antibodies and related proteins, particularly humanized monoclonal antibodies;IFN gamma-specific antibodies, peptibodies, related proteins, and the like, including but not limited to, human IFN gamma-specific antibodies, and fully human anti-IFN gamma antibodies; TALL-1-specific antibodies, peptibodies, related proteins, and the like, as well as other TALL-specific binding proteins; parathyroid hormone ("PTH")-specific antibodies, peptibodies, related proteins, and the like; thrombopoietin receptor ("TPO-R")-specific antibodies, peptibodies, related proteins, and the like; fully human monoclonal antibodies that neutralize hepatocyte growth factor / scatter factor (HGF / SF) Hepatocyte growth factor ("HGF")-specific antibodies, peptibodies, related proteins, etc., including those that target the HGF / SF:c-Met axis (HGF / SF:c-Met), such as clonal antibodies; TRAIL-R2-specific antibodies, peptibodies, related proteins, etc.; activin A-specific antibodies, peptibodies, proteins, etc.; TGF-beta-specific antibodies, peptibodies, related proteins, etc.; amyloid beta protein-specific antibodies, peptibodies, related proteins, etc.; proteins that bind to c-Kit and / or other stem cell factor receptors, including, but not limited to, those c-Kit specific antibodies, peptibodies, related proteins, etc., including but not limited to; OX40L specific antibodies, peptibodies, related proteins, etc., including but not limited to proteins that bind to OX40L and / or other ligands of the OX40 receptor; Activase® (alteplase, tPA), Aranesp® (darbepoetin alfa), erythropoietin [30-asparagine, 32-threonine, 87-valine, 88-asparagine, 90-threonine], darbepoetin alfa, de novo hematopoietic stimulating protein Protein (NESP); Epogen® (epoetin alfa, or erythropoietin); GLP-1, Avonex® (interferon beta-1a); Bexxar® (tositumomab, an anti-CD22 monoclonal antibody); Betaseron® (interferon-beta); Campath® (alemtuzumab, an anti-CD52 monoclonal antibody); Dynepo® (epoetin delta); Velcade® (bortezomib); MLN0002 (anti-α4β7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb);Enbrel® (etanercept, TNF receptor / Fc fusion protein, TNF blocker); Eprex® (epoetin alfa); Erbitux® (cetuximab, anti-EGFR / HER1 / c-ErbB-1); Genotropin® (somatropin, human growth hormone); Herceptin® (trastuzumab, anti-HER2 / neu(erbB2) receptor mAb); Kanjinti™ (trastuzumab-anns) anti-HER2 monoclonal antibody, a biosimilar of Herceptin®, or another product containing trastuzumab for the treatment of breast or gastric cancer; Humatrope® (somatropin, human growth hormone); Humira® (adalimumab); Vectibix® trademark) (panitumumab); Xgeva® (denosumab); Prolia® (denosumab), immunoglobulin G2 human monoclonal antibody against RANK ligand; Enbrel® (etanercept, TNF-receptor / Fc fusion protein, TNF blocker); Nplate® (romiplostim), rilotumumab, ganitumab, conatumumab, brodalumab, insulin in solution; Infergen® (interferon alfacon-1); Natrecor® (nesiritide; recombinant human B-type natriuretic peptide (hBNP); Kineret® (anakinra); Leukine® (sargamostim, rhuGM-CSF); LymphoCide® (epratuzumab, anti-CD22 mAb); Benlysta™ (lymphostat B, belimumab, anti-BlyS mAb); Metalyse® (tenecteplase, t-PA analog); Mircera® (methoxypolyethylene glycol-epoetin beta); Mylotarg® (gemtuzumab ozogamicin); Raptiva® (efalizumab); Cimzia® (certolizumab pegol, CDP 870); Soliris™ (eculizumab); pexelizumab (anti-complement C5); Numax® (MEDI-524); Lucentis® (ranibizumab);Panorex® (17-1A, edrecolomab); Trabio® (lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4); Osidem® (IDM-1); OvaRex® (B43.13); Nuvion® (vigilizumab); cantuzumab mertansine (huC242-DM1); NeoRecormon® (epoetin beta); Neumega® (oprelvekin, human interleukin-11); Orthoclone OKT3® (muromonab-CD3, anti-CD3 monoclonal antibody); Procrit® (epoetin alfa); Remicade® (infliximab, anti-TNFα monoclonal antibody); Reopro® (abciximab, anti-GP IL6 / IL6 receptor monoclonal antibody; Actemra® (anti-IL6 receptor mAb); Avastin® (bevacizumab), HuMax-CD4 (zanolimumab); Mvasi™ (bevacizumab-awwb); Rituxan® (rituximab, anti-CD20 mAb); Tarceva® (erlotinib); Roferon-A® (interferon alpha-2a); Simulect® (basiliximab); Prexige® (lumiracoxib); Synagis® (palivizumab), 145c7-CHO (anti-IL15 antibody, see U.S. Pat. No. 7,153,507); Tysabri® (natalizumab, anti-α4 integrin mAb); Valortim® (MDX-1303, anti-B. anthracis protective antigen mAb); ABthrax™; Xolair® (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (the Fc portion of human IgG1 and the extracellular domain of both IL-1 receptor components (type I receptor and receptor accessory protein)); VEGF trap (IgG1 Ig domain of VEGFR1 fused to Fc; Zenapax® (daclizumab); Zenapax® (daclizumab, anti-IL-2Rα mAb);Zevalin® (ibritumomab tiuxetan); Zetia® (ezetimibe); Orencia® (atacicept, TACI-Ig); anti-CD80 monoclonal antibody (galiximab); anti-CD23 mAb (lumiliximab); BR2-Fc (huBR3 / huFc fusion protein, soluble BAFF antagonist); CNTO 148 (golimumab, anti-TNFα mAb); HGS-ETR1 (mapatuzumab; human anti-TRAIL receptor-1 mAb); HuMax-CD20 (ocrelizumab, anti-CD20 human mAb); HuMax-EGFR (zalutumumab); M200 (volociximab, anti-α5β1 integrin mAb); MDX-010 (ipilimumab, anti-CTLA-4 mAb, and VEGFR-1 (IMC-18F1); anti-BR3 mAbs; anti-C. difficile toxin A and toxin BC mAbs MDX-066 (CDA-1) and MDX-1388; anti-CD22 dsFv-PE38 conjugates (CAT-3888 and CAT-8015); anti-CD25 mAb (HuMax-TAC); anti-CD3 mAb (NI-0401); adecatumumab; anti-CD30 mAb (MDX-060); MDX-1333 (anti-IFNAR); anti-CD38 mAb (HuMax CD38), anti-CD40L mAb; anti-Cripto mAb; anti-CTGF idiopathic pulmonary fibrosis stage 1 fibrogen (FG-3019); anti-CTLA4 mAb; anti-eotaxin 1 mAb (CAT-213); anti-FGF8 mAb; anti-ganglioside GD2 mAb;Anti-ganglioside GM2 mAb;Anti-GDF-8 human mAb (MYO-029);Anti-GM-CSF receptor mAb (CAM-3001);Anti-HepC mAb (HuMax HepC);Anti-IFNα mAb (MEDI-545, MDX-198);Anti-IGF1R mAb;Anti-IGF-1R mAb (HuMax-Inflam);Anti-IL12 mAb (ABT-874); anti-IL12 / IL23 mAb (CNTO 1275); anti-IL13 mAb (CAT-354); anti-IL2Ra mAb (HuMax-TAC); anti-IL5 receptor mAb; anti-integrin receptor mAb (MDX-018, CNTO 95);Anti-IP10 ulcerative colitis mAb (MDX-1100);BMS-66513;Anti-mannose receptor / hCGβ mAb (MDX-1307); anti-mesothelin dsFv-PE38 conjugate (CAT-5001); anti-PD1 mAb (MDX-1106 (ONO-4538)); anti-PDGFRα antibody (IMC-3G3); anti-TGFβ mAb (GC-1008); anti-TRAIL receptor-2 human mAb (HGS-ETR2); anti-TWEAK mAb; anti-V; EGFR / Flt-1 mAb, and anti-ZP3 mAb (HuMax-ZP3).

[0090] In some embodiments, the drug delivery device may contain or be used in conjunction with a sclerostin antibody, such as, but not limited to, romosozumab, brosozumab, BPS 804 (Novartis), Evenity™ (romosozumab-aqqg), or another product containing romosozumab for the treatment of postmenopausal osteoporosis and / or fracture healing, and in other embodiments, a monoclonal antibody (IgG) that binds to human proprotein convertase subtilisin / kexin type 9 (PCSK9). Such PCSK9-specific antibodies include, but are not limited to, Repatha® (evolocumab) and Praluent® (alirocumab). In other embodiments, the drug delivery device may contain or be used in conjunction with rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, or panitumumab. In some embodiments, the reservoir of the drug delivery device may be loaded with, and the device may be used in conjunction with, IMLYGIC® (talimogene laherparepvec) or another oncolytic HSV for the treatment of melanoma or other cancers, including, but not limited to, OncoVEX GALV / CD; OrienX010; G207, 1716; NV1020; NV12023; NV1034; and NV1042. In some embodiments, the drug delivery device may contain, or be used in conjunction with, an endogenous tissue inhibitor of metalloproteinases (TIMP), such as, but not limited to, TIMP-3. In some embodiments, the drug delivery device may contain, or be used in conjunction with, Aimovig® (erenumab-aooe), an anti-human CGRP-R (calcitonin gene-related peptide type 1 receptor), or another product containing erenumab for the treatment of migraines. Antagonistic antibodies of the human calcitonin gene-related peptide (CGRP) receptor, such as, but not limited to, erenumab, and bispecific antibody molecules that target the CGRP receptor and other headache targets, may also be delivered using the drug delivery devices of the present disclosure.Additionally, bispecific T-cell engager (BiTE®) antibodies, such as, but not limited to, BLINCYTO® (blinatumomab), can be used in or with the drug delivery devices of the present disclosure. In some embodiments, the drug delivery device may contain or be used in conjunction with an APJ large molecule agonist, such as, but not limited to, apelin or an analog thereof. In some embodiments, a therapeutically effective amount of anti-thymic stromal lymphopoietin (TSLP) or a TSLP receptor antibody is used in or with the drug delivery device of the present disclosure. In some embodiments, the drug delivery device may contain or be used in conjunction with Avsola™ (infliximab-axxq), an anti-TNFα monoclonal antibody, a biosimilar of Remicade® (infliximab) (Janssen Biotech, Inc.), or another product containing infliximab for the treatment of autoimmune diseases. In some embodiments, the drug delivery device may contain or be used in conjunction with Kyprolis® (carfilzomib), (2S)—N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide, or another product containing carfilzomib for the treatment of multiple myeloma. In some embodiments, the drug delivery device may contain or be used in conjunction with Otezla® (apremilast), N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide, or another product containing apremilast for the treatment of various inflammatory diseases.In some embodiments, the drug delivery device may contain or be used in conjunction with Parsabiv™ (etelcalcetide HCl, KAI-4169) or another product containing etelcalcetide HCl for the treatment of secondary hyperparathyroidism (sHPT), such as in patients with chronic kidney disease (KD) on hemodialysis. In some embodiments, the drug delivery device may contain or be used in conjunction with ABP 798 (rituximab), a biosimilar candidate for Rituxan® / MabThera™, or another product containing an anti-CD20 monoclonal antibody. In some embodiments, the drug delivery device may contain or be used in conjunction with a VEGF antagonist, such as a non-antibody VEGF antagonist, and / or a VEGF-Trap (Ig domain 2 from VEGFR1 and Ig domain 3 from VEGFR2 fused to the Fc domain of IgG1), such as aflibercept. In some embodiments, the drug delivery device may contain or be used in conjunction with ABP 959 (eculizumab), a biosimilar candidate for Soliris®, or another product containing a monoclonal antibody that specifically binds to complement protein C5. In some embodiments, the drug delivery device may contain or be used in conjunction with rozivafusp alfa (formerly AMG 570), a novel bispecific antibody-peptide conjugate that simultaneously blocks ICOSL and BAFF activity. In some embodiments, the drug delivery device may contain or be used in conjunction with omecamtib mecarbil, a small molecule selective cardiac myosin activator or myotrope that directly targets the cardiac contractile machinery, or another product containing a small molecule selective cardiac myosin activator. In some embodiments, the drug delivery device may contain sotorasib (formerly known as AMG 510), a KRAS inhibitor. G12C Small molecule inhibitors, or KRAS G12CThe drug delivery device may contain or be used in conjunction with another product containing a small molecule inhibitor. In some embodiments, the drug delivery device may contain or be used in conjunction with tezepelumab, a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), or another product containing a human monoclonal antibody that inhibits the action of TSLP. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 714, a human monoclonal antibody that binds to interleukin-15 (IL-15), or another product containing a human monoclonal antibody that binds to interleukin-15 (IL-15). In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 890, a small interfering RNA (siRNA) that reduces lipoprotein(a), also known as Lp(a), or another product containing a small interfering RNA (siRNA) that reduces lipoprotein(a). In some embodiments, the drug delivery device may contain or be used in conjunction with ABP 654 (a human IgG1 kappa antibody), a biosimilar candidate for Stelara®, or another product that contains a human IgG1 kappa antibody and / or binds to the p40 subunit of the human cytokines interleukin (IL)-12 and IL-23. In some embodiments, the drug delivery device may contain or be used in conjunction with Amjevita™ or Amgevita™ (formerly ABP 501) (a mab anti-TNF human IgG1), a biosimilar candidate for Humira®, or another product containing a human mab anti-TNF human IgG1. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 160, or another product containing a half-life extended (HLE) anti-prostate specific membrane antigen (PSMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. In some embodiments, the drug delivery device may contain or be used in conjunction with another product containing AMG 119 or a delta-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T cell) cell therapy.In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 119, or another product containing a delta-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T cell) cell therapy. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 133, or another product containing a gastric inhibitory polypeptide receptor (GIPR) antagonist and a GLP-1R agonist. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 171, or another product containing a growth differentiation factor 15 (GDF15) analog. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 176, or another product containing a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 199, or another product containing a half-life extended (HLE) bispecific T-cell engager construct (BiTE®). In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 256, or another product containing an anti-PD-1 x IL21 mutein and / or IL-21 receptor agonist designed to selectively activate the interleukin-21 (IL-21) pathway in programmed cell death-1 (PD-1)-positive cells. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 330, or another product containing an anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 404, or another product containing a human anti-programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors.In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 427, or another product containing a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 BiTE® (bispecific T-cell engager) construct. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 430, or another product containing an anti-Jagged-1 monoclonal antibody. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 506, or another product containing a multispecific FAP x 4-1BB-targeted DARPin® biologic being investigated as a treatment for solid tumors. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 509, or another product containing a bivalent T-cell engager and designed using XmAb® 2+1 technology. In some embodiments, the drug delivery device comprises AMG 562, or half-life extended (HLE) CD19 x anti-CD3 BiTE® (bispecific T cells. In some embodiments, the drug delivery device may contain or be used in conjunction with another product containing a half-life extended (HLE) anti-human CD33 x anti-anti-human CD3 BiTE® (bispecific T cell engager) construct. In some embodiments, the drug delivery device may contain or be used in conjunction with another product containing efavalukin alfa (formerly AMG 592) or an IL-2 mutein Fc fusion protein. In some embodiments, the drug delivery device may contain or be used in conjunction with another product containing AMG 596 or a CD3 x epidermal growth factor receptor vIII (EGFRvIII) BiTE® (bispecific T cell engager) molecule. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 673 or a half-life extended (HLE) anti-human CD33 x anti-anti-human CD3 BiTE® (bispecific T cell engager) construct. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 701 or another product containing a half-life extended (HLE) anti-B cell maturation antigen (BCMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 757 or another product containing a half-life extended (HLE) anti-delta-like ligand 3 (DLL3) x anti-CD3 BiTE® (bispecific T cell engager) construct. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 910 or another product containing a half-life extended (HLE) epithelial cell tight junction component protein claudin 18.2 x anti-CD3 BiTE® (bispecific T cell engager) construct.

[0091] Although the drug delivery devices, assemblies, components, subsystems, and methods have been described in terms of exemplary embodiments, they are not limited to the exemplary embodiments. The detailed description should be construed as merely exemplary and does not describe every possible embodiment of the present disclosure. Many alternative embodiments can be implemented using either current technology or technology developed after the filing date of this patent, and such embodiments will still fall within the scope of the claims that define the invention disclosed herein.

[0092] Those skilled in the art will appreciate that numerous modifications, variations, and combinations can be made to the above-described embodiments without departing from the spirit and scope of the invention disclosed herein, and that such modifications, variations, and combinations are to be construed as being within the scope of the inventive concept.

Claims

1. A drug delivery device comprising: a housing having an opening; a drug reservoir including a delivery member having an insertion end configured to extend at least partially through the opening in the housing; Plunger and a drive mechanism operable to drive the plunger to expel the drug from the drug reservoir through the delivery member; an indicator operably coupled to the drive mechanism to generate a continuous or repeating audible signal during drug delivery and to cease generating the continuous or repeating audible signal when drug delivery is complete; 10. A drug delivery device comprising:

2. A drug delivery device as described in claim 1, wherein the indicator is rotatable relative to the housing.

3. A drug delivery device as described in claim 2, wherein, by activating the drive mechanism, the drive mechanism rotates the indicator relative to the housing.

4. A drug delivery device as described in claim 3, wherein the drive mechanism stops rotation of the indicator when drug delivery is completed.

5. A drug delivery device as described in claim 3 or 4, wherein the drive mechanism includes a rotary biasing member held in an initially biased state and a mechanical linkage that operably couples the rotary biasing member and the plunger, the mechanical linkage being configured to rotate as the rotary biasing member is de-energized.

6. The drug delivery device of claim 5, wherein the mechanical linkage includes a plunger guide having a proximal end and a distal end, the plunger being at least partially positioned within the distal end of the plunger guide, and the proximal end of the plunger guide being coupled to the indicator such that the indicator rotates in unison with the plunger guide.

7. A first plurality of protrusions coupled to the display; a second plurality of protrusions arranged concentrically with the first plurality of protrusions; Including, 7. The drug delivery device of claim 1, wherein the first plurality of protrusions slidably engage with the second plurality of protrusions to generate the continuous or repetitive audible signal during drug delivery.

8. A drug delivery device as described in claim 7, wherein the second plurality of protrusions are arranged around the first plurality of protrusions.

9. A drug delivery device as described in claim 8, wherein during drug delivery, the first plurality of protrusions rotates relative to the second plurality of protrusions such that each protrusion of the first plurality of protrusions slidably engages with one or more protrusions of the second plurality of protrusions.

10. A drug delivery device described in any one of claims 7 to 9, wherein each protrusion of the first plurality of protrusions extends radially outward and each protrusion of the second plurality of protrusions extends radially inward.

11. A drug delivery device as described in any one of claims 7 to 10, wherein each protrusion of the first plurality of protrusions includes a flexible arm that is movable between a first radial position and a second radial position when the flexible arm engages with a respective protrusion of the second plurality of protrusions.

12. A drug delivery device comprising: a housing having an opening and a housing rotation prevention portion; a drug reservoir including a delivery member having an insertion end configured to extend at least partially through the opening in the housing; Plunger and a drive mechanism operable to drive the plunger to expel the drug from the drug reservoir through the delivery member; an end cap removably coupled to the housing adjacent the opening when in a storage position, the end cap having an end cap rotation restraint portion adjacent to and substantially aligned with the housing rotation restraint portion when the end cap is in the storage position; 10. A drug delivery device comprising:

13. A drug delivery device as described in claim 12, wherein one of the end cap rotation inhibitor portion and the housing rotation inhibitor portion includes a protrusion, and the other of the end cap rotation inhibitor portion and the housing rotation inhibitor portion includes a second opening configured to accommodate the protrusion when the end cap is in the storage position.

14. A drug delivery device comprising: a housing having an opening; a drug reservoir including a housing portion defining a longitudinal axis and a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state; a plunger movable distally to expel a drug from the drug reservoir through the delivery member; a rotary biasing member configured to be held in an initial biased state and to rotate about said longitudinal axis when released; a mechanical linkage operably coupled to the plunger and the rotary biasing member, the mechanical linkage configured to convert rotation caused by release of the rotary biasing member into movement of the plunger in the distal direction.

15. The drug delivery device of claim 14, wherein the mechanical linkage is configured to convert rotation caused by release of the rotary biasing member into movement of the plunger in the distal direction without rotating the plunger.

16. A drug delivery device as described in claim 14 or 15, wherein the mechanical linkage includes a nut having a threaded inner surface that engages with the threaded outer surface of the plunger.

17. A drug delivery device comprising: a housing having an opening; a drug reservoir including a delivery member having an insertion end configured to extend at least partially through the opening in the housing; A plunger; a drive mechanism operable to drive the plunger distally to expel a drug from the drug reservoir through the delivery member; a guard movably positioned adjacent the opening and operably coupled to the drive mechanism; a lock selectively engageable with the guard to limit movement of the guard in a proximal direction; an indicator operably coupled to the drive mechanism to generate a continuous or repetitive audible signal during drug delivery; 10. A drug delivery device comprising:

18. A drug delivery device as described in claim 17, wherein the indicator stops generating the continuous or repetitive audible signal when drug delivery is completed.

19. A drug delivery device as described in claim 17 or 18, wherein the indicator is rotatable relative to the housing.

20. A drug delivery device as described in claim 17, wherein by activating the drive mechanism, the drive mechanism rotates the indicator relative to the housing, and the drive mechanism stops the rotation of the indicator when drug delivery is completed.

Images